Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $2.2 million.

  • Lisata Therapeutics' Net Cash Flow rose 12449.28% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$455000.0, marking a year-over-year increase of 9646.0%. This contributed to the annual value of -$6.3 million for FY2024, which is 3369.3% up from last year.
  • Latest data reveals that Lisata Therapeutics reported Net Cash Flow of $2.2 million as of Q3 2025, which was up 12449.28% from -$3.4 million recorded in Q2 2025.
  • Over the past 5 years, Lisata Therapeutics' Net Cash Flow peaked at $8.7 million during Q3 2023, and registered a low of -$9.8 million during Q4 2023.
  • For the 3-year period, Lisata Therapeutics' Net Cash Flow averaged around -$1.2 million, with its median value being -$3.2 million (2024).
  • Per our database at Business Quant, Lisata Therapeutics' Net Cash Flow plummeted by 20184.69% in 2024 and then surged by 64652.11% in 2025.
  • Lisata Therapeutics' Net Cash Flow (Quarter) stood at -$9.8 million in 2023, then soared by 66.85% to -$3.2 million in 2024, then surged by 166.8% to $2.2 million in 2025.
  • Its Net Cash Flow stands at $2.2 million for Q3 2025, versus -$3.4 million for Q2 2025 and $4.0 million for Q1 2025.